FDA 483 - Daniel Norman, M.D. - September 02, 2020

An FDA inspection of Daniel Norman, M.D. in Santa Monica, CA, a clinical investigator, revealed a significant deviation from an investigational plan. The firm failed to conduct an investigation in accordance with the signed statement of investigator and protocol. Specifically, subjects were enrolled in a study while on prohibited concomitant medications, indicating a lack of adherence to study procedures.